Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
MNVAFDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
August 14, 2025Earnings
Read more →FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia